Biomarin Pharmaceutical (MIL:1BMRN) Beginning Cash Position : €695 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Beginning Cash Position?

Biomarin Pharmaceutical's Beginning Cash Position for the quarter that ended in Mar. 2024 was €695 Mil.

Biomarin Pharmaceutical's quarterly Beginning Cash Position increased from Sep. 2023 (€651 Mil) to Dec. 2023 (€720 Mil) but then declined from Dec. 2023 (€720 Mil) to Mar. 2024 (€695 Mil).

Biomarin Pharmaceutical's annual Beginning Cash Position declined from Dec. 2021 (€575 Mil) to Dec. 2022 (€554 Mil) but then increased from Dec. 2022 (€554 Mil) to Dec. 2023 (€664 Mil).

Biomarin Pharmaceutical Beginning Cash Position Historical Data

The historical data trend for Biomarin Pharmaceutical's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Beginning Cash Position Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

444.58

359.58

574.50

554.39

664.40

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															676.71	535.41	650.64	720.22	694.72

Biomarin Pharmaceutical Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Biomarin Pharmaceutical Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BMRN:USA BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines